Premium
Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy
Author(s) -
Press Robert H.,
Zhang Chao,
Cassidy Richard J.,
Ferris Matthew J.,
Zhong Jim,
Steuer Conor E.,
Pillai Rathi N.,
Owonikoko Taofeek K.,
Kahn Shan,
Ramalingam Suresh S.,
Patel Pretesh R.,
Curran Walter J.,
Shu HuiKuo G.,
Sica Gabriel L.,
Higgins Kristin A.
Publication year - 2018
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.31589
Subject(s) - medicine , kras , pten , anaplastic lymphoma kinase , oncology , radiosurgery , hazard ratio , adenocarcinoma , lung cancer , radiation therapy , univariate analysis , cancer , multivariate analysis , pi3k/akt/mtor pathway , apoptosis , confidence interval , biochemistry , chemistry , colorectal cancer , malignant pleural effusion
BACKGROUND Treatment for advanced lung adenocarcinoma (AC) has become increasingly personalized based on molecular results. However, for patients with AC brain metastases (BMs), intracranial outcomes based on molecular subtype and the frequency of molecular aberrations are less well defined. This study sought to report targeted next‐generation sequencing results and investigate molecularly based outcomes for patients with AC‐BMs treated with radiotherapy. METHODS The records of 132 patients with AC‐BMs treated at Emory University from September 2008 to August 2016 with successful next‐generation sequencing were reviewed. Rates of local disease recurrence, distant brain failure (DBF), and salvage whole‐brain radiotherapy (WBRT) were estimated using cumulative incidence with competing risk analysis. Univariate and multivariate analyses were performed. RESULTS The most common aberrations included tumor protein 53 (TP53) (60%), KRAS (29%), epidermal growth factor receptor (EGFR) (20.5%), phosphatase and tensin homolog (PTEN) loss (15.5%), and MET amplification (13%). The majority of patients (62%) were treated with stereotactic radiosurgery alone. In these patients, KRAS mutation, anaplastic lymphoma kinase (ALK) rearrangement, and having ≥ 6 BMs were associated with an increased risk of salvage WBRT ( P < .05). KRAS mutation remained significant for an increased risk of salvage WBRT when compared with EGFR/ALK/KRAS‐negative patients (hazard ratio, 5.17; P < .05), despite a similar risk of DBF. PTEN loss was associated with increased risk of DBF ( P < .05), whereas EGFR and ALK aberrations were associated with a decreased risk of local disease recurrence ( P < .05). CONCLUSIONS The results of the current study quantified the frequency of genetic aberrations in patients with AC‐BMs and demonstrated their association with intracranial outcomes. In particular, a cohort of patients with KRAS mutations and ≥6 BMs were identified to be at high risk of requiring salvage WBRT after undergoing upfront stereotactic radiosurgery.